Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACST NASDAQ:PYXS NASDAQ:SPRO NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsPYXSPyxis Oncology$1.82-2.2%$1.28$0.83▼$5.39$115.35M1.14775,544 shs723,147 shsSPROSpero Therapeutics$1.90-2.6%$2.22$0.51▼$3.22$109.74M1.46378,536 shs391,231 shsZNTLZentalis Pharmaceuticals$1.49-4.5%$1.52$1.01▼$5.44$112.53M1.76805,086 shs505,455 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%+34.05%PYXSPyxis Oncology-0.53%+15.53%+78.85%+55.00%-48.90%SPROSpero Therapeutics+0.52%-8.88%-17.37%-31.10%+45.52%ZNTLZentalis Pharmaceuticals+6.85%-11.86%+10.64%+16.42%-52.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsPYXSPyxis Oncology$1.82-2.2%$1.28$0.83▼$5.39$115.35M1.14775,544 shs723,147 shsSPROSpero Therapeutics$1.90-2.6%$2.22$0.51▼$3.22$109.74M1.46378,536 shs391,231 shsZNTLZentalis Pharmaceuticals$1.49-4.5%$1.52$1.01▼$5.44$112.53M1.76805,086 shs505,455 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%+34.05%PYXSPyxis Oncology-0.53%+15.53%+78.85%+55.00%-48.90%SPROSpero Therapeutics+0.52%-8.88%-17.37%-31.10%+45.52%ZNTLZentalis Pharmaceuticals+6.85%-11.86%+10.64%+16.42%-52.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsidePYXSPyxis Oncology 2.67Moderate Buy$7.75325.82% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00163.16% UpsideZNTLZentalis Pharmaceuticals 2.67Moderate Buy$8.20450.34% UpsideCurrent Analyst Ratings BreakdownLatest ACST, ZNTL, SPRO, and PYXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.009/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/18/2025PYXSPyxis OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/7/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ZNTLZentalis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/APYXSPyxis Oncology$16.15M6.99N/AN/A$2.03 per share0.90SPROSpero Therapeutics$34.09M3.14N/AN/A$0.85 per share2.24ZNTLZentalis Pharmaceuticals$67.43M1.59N/AN/A$4.73 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/APYXSPyxis Oncology-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$165.84M-$2.26N/AN/AN/AN/A-51.62%-40.28%11/11/2025 (Estimated)Latest ACST, ZNTL, SPRO, and PYXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PYXSPyxis Oncology-$0.36-$0.30+$0.06-$0.30N/A$2.82 million8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 million8/6/2025Q2 2025ZNTLZentalis Pharmaceuticals-$0.56-$0.37+$0.19-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.063.16%N/AN/A N/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86PYXSPyxis OncologyN/A5.655.65SPROSpero TherapeuticsN/A3.973.97ZNTLZentalis PharmaceuticalsN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%PYXSPyxis Oncology39.09%SPROSpero Therapeutics25.60%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%PYXSPyxis Oncology10.60%SPROSpero Therapeutics5.50%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionablePYXSPyxis Oncology6062.02 million55.44 millionOptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableZNTLZentalis Pharmaceuticals16072.14 million70.76 millionOptionableACST, ZNTL, SPRO, and PYXS HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9 at 1:05 PM | seekingalpha.comNuveen LLC Takes $807,000 Position in Zentalis Pharmaceuticals, Inc. $ZNTLSeptember 4, 2025 | marketbeat.comZentalis Pharmaceuticals Grants Stock Options to New Employees as Part of Inducement PlanSeptember 2, 2025 | quiverquant.comQZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comZentalis Pharmaceuticals Announces New Chief Legal OfficerAugust 26, 2025 | msn.comZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate SecretaryAugust 26, 2025 | globenewswire.comGuggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)August 19, 2025 | theglobeandmail.comZentalis Pharmaceuticals (ZNTL) Gets a Buy from TD CowenAugust 18, 2025 | theglobeandmail.comZentalis (ZNTL) Q2 Loss Narrows 70%August 18, 2025 | theglobeandmail.comZentalis price target lowered to $5 from $6 at Wells FargoAugust 8, 2025 | msn.comZentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational ProgressAugust 6, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the companyJuly 24, 2025 | finance.yahoo.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHere's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn SituationJune 26, 2025 | finance.yahoo.comZentalis Pharmaceuticals shareholders elect three directors at annual meetingJune 20, 2025 | investing.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressMay 14, 2025 | globenewswire.comFirst Patient Dosed With Azenosertib in Cyclin E1+ Ovarian CancerMay 3, 2025 | curetoday.comCZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025ACST, ZNTL, SPRO, and PYXS Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Pyxis Oncology NASDAQ:PYXS$1.82 -0.04 (-2.15%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.10%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Spero Therapeutics NASDAQ:SPRO$1.90 -0.05 (-2.56%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.01 (+0.26%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.49 -0.07 (-4.49%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.34%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
